Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

Mather et al., American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832

Mather et al., Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19, American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832

Aug 2020 Source PDF

Twitter
Facebook

All Studies Meta

PSM retrospective 878 hospitalized patients in the USA, 83 with existing famotidine use, showing significantly lower mortality with treatment.

Important missing comments or errors? Let us know.

risk of death, 61.4% lower, HR 0.39, p = 0.004, treatment 83, control 689, propensity score matching, Cox proportional hazards.

risk of death/intubation, 50.5% lower, HR 0.49, p = 0.003, treatment 83, control 689, propensity score matching, Cox proportional hazards.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Mather et al., 26 Aug 2020, retrospective, USA, peer-reviewed, 3 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Famotidine All

Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19

MS. Jeffrey F Mather, PhD Richard L Seip, MD Raymond G Mckay

American Journal of Gastroenterology, doi:10.14309/ajg.0000000000000832

INTRODUCTION: To compare outcomes in patients hospitalized with coronavirus (COVID-19) receiving famotidine therapy with those not receiving famotidine.

Study Highlights WHAT IS KNOWN? 3 Despite multiple trials that are currently underway to investigate the safety and efficacy of a large number of possible therapeutic agents, no drug to date has been shown to reduce COVID-19 mortality. 3 It has been postulated that famotidine's effect is achieved via its antagonism or inverse agonism of the histamine-2 receptor, inferring that the SARS-CoV-2 infection that results in COVID-19 is at least partially mediated by pathological histamine release. COVID-19 Mather et al.

References

Anand, Ziebuhr, Wadhwani, Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs, Science

Borrell, New York clinical trial quietly tests heartburn remedy against coronavirus

Bourinbaiar, Fruhstorfer, The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: Identification of a new class of antiviral agents, Life Sci

Burde, Seifert, Buschauer, Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H2-receptors, Naunyn Schmiedebergs Arch Pharmacol

Caughey, Raymond, Wolters, Angiotensin II generation by mast cell alpha-and beta-chymases, Biochim Biophys Acta

Eliezer, Hautefort, Hamel, Sudden and complete olfactory loss of function as a possible symptom of COVID-19, JAMA Otolaryngol Head Neck Surg

Ezeamuzie, Philips, Histamine, 2) receptors mediate the inhibitory effect of histamine on human eosinophil degranulation, Br J Pharmacol

Flamand, Plante, Picard, Histamine-induced inhibition of leukotriene biosynthesis in human neutrophils: Involvement of the H2 receptor and cAMP, Br J Pharmacol

Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study, Gastroenterology, doi:10.1053/j.gastro.2020.05.053

Giacomelli, Pezzati, Conti, Self-reported olfactory and taste disorders in SARS-CoV-2 patients: A cross-sectional study, Clin Infect Dis

Janowitz, Gablenz, Pattinson, Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: A case series, Gut

Kritas, Ronconi, Caraffa, Mast cells contribute to coronavirus-induced inflammation: New anti-inflammatory strategy, J Biol Regul Homeost Agents

Malone, Tisdall, Smith, COVID-19: famotidine, histamine, mast cells, and mechanisms, Preprint Res Sq, doi:10.21203/rs.3.rs-30934/v2

Marshall, Portales-Cervantes, Leong, Mast cell responses to viruses and pathogen products, Int J Mol Sci

Metcalfe, Baram, Mekori, Mast cells, Physiol Rev

Mukai, Tsai, Saito, Mast cells as sources of cytokines, chemokines, and growth factors, Immunol Rev

Rabier, Damon, Chanez, Inhibition by histamine of plateletactivating-factor-induced neutrophil chemotaxis in bronchial asthma, Int Arch Allergy Appl Immunol

Theoharides, Alysandratos, Angelidou, Mast cells and inflammation, Biochim Biophys Acta

Tian, Hu, Niu, Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer, J Thorac Oncol

Wadee, Anderson, Sher, In vitro effects of histamine on migration, Int Arch Allergy Appl Immunol

Wu, Liu, Yang, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm Sin B

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit